OTCMKTS:BAYRY Bayer Aktiengesellschaft (BAYRY) Stock Price, News & Analysis $14.07 -0.24 (-1.68%) As of 09/10/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsNews and TrendsSEC FilingsShort Interest About Bayer Aktiengesellschaft Stock (OTCMKTS:BAYRY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BAYRY alerts:Sign Up Key Stats Today's Range$14.06▼$14.2050-Day Range$13.13▼$15.1952-Week Range$7.48▼$15.23Volume325,835 shsAverage Volume364,329 shsMarket Capitalization$55.30 billionP/E RatioN/ADividend Yield0.14%Price TargetN/AConsensus RatingBuy Company Overview Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer’s American depositary shares trade over the counter under the symbol BAYRY. The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, neurology and specialty therapeutics. Consumer Health offers nonprescription products, including brands in pain relief, allergy care, dermatology, nutritional supplements and digestive health. Crop Science supplies seeds, crop-protection products and digital tools designed to support farmers and improve agricultural productivity. Bayer has expanded its operations internationally through internal research and development, partnerships and acquisitions, including the acquisition of Monsanto in 2018, which strengthened its seeds and agricultural technology business. Bill Anderson has served as Bayer’s chief executive officer since June 2023 and also leads the company’s ongoing organizational transformation.AI Generated. May Contain Errors. Read More Bayer Aktiengesellschaft Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreBAYRY MarketRank™: Bayer Aktiengesellschaft scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingBuy Consensus RatingBayer Aktiengesellschaft has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBayer Aktiengesellschaft has only been the subject of 2 research reports in the past 90 days.Read more about Bayer Aktiengesellschaft's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth4.69% Earnings GrowthEarnings for Bayer Aktiengesellschaft are expected to grow by 4.69% in the coming year, from $1.28 to $1.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bayer Aktiengesellschaft is -27.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bayer Aktiengesellschaft is -27.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBayer Aktiengesellschaft has a PEG Ratio of 2.15. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBayer Aktiengesellschaft has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bayer Aktiengesellschaft's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Bayer Aktiengesellschaft has been sold short.Short Interest Ratio / Days to CoverBayer Aktiengesellschaft has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bayer Aktiengesellschaft has recently decreased by 80.77%, indicating that investor sentiment is improving significantly. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldBayer Aktiengesellschaft has a dividend yield of 0.17%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthBayer Aktiengesellschaft does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Bayer Aktiengesellschaft will have a dividend payout ratio of 1.49% next year. This indicates that Bayer Aktiengesellschaft will be able to sustain or increase its dividend.Read more about Bayer Aktiengesellschaft's dividend. News and Social Media3.3 / 5News Sentiment0.25 News SentimentBayer Aktiengesellschaft has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Bayer Aktiengesellschaft this week, compared to 5 articles on an average week.Search Interest10 people have searched for BAYRY on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.MarketBeat Follows2 people have added Bayer Aktiengesellschaft to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bayer Aktiengesellschaft insiders have not sold or bought any company stock.Percentage Held by InstitutionsBayer Aktiengesellschaft has minimal institutional ownership at this time.Read more about Bayer Aktiengesellschaft's insider trading history. Receive BAYRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bayer Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BAYRY Stock News HeadlinesBayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update1 hour ago | americanbankingnews.comBayer Launches Nationwide Science Delivers Tour to Take Science on the RoadSeptember 10 at 3:54 PM | businesswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Bayer Expands Real World Surveillance for Darolutamide in Indian Prostate Cancer MarketSeptember 10 at 12:51 PM | tipranks.comU.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung CancerSeptember 9 at 10:21 PM | businesswire.comBayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Rating of "Buy" from AnalystsSeptember 9 at 3:45 AM | americanbankingnews.comBayer Aktiengesellschaft (BAYRY) Discusses Innovation Strategy and Progress on Five-Year Growth Framework in Crop Science Division TranscriptSeptember 2, 2026 | seekingalpha.comBayer says Crop Science unit makes progress on product launchesSeptember 2, 2026 | reuters.comSee More Headlines BAYRY Stock Analysis - Frequently Asked Questions How have BAYRY shares performed this year? Bayer Aktiengesellschaft's stock was trading at $10.82 at the beginning of 2026. Since then, BAYRY stock has increased by 30.0% and is now trading at $14.07. How were Bayer Aktiengesellschaft's earnings last quarter? Bayer Aktiengesellschaft (OTCMKTS:BAYRY) announced its earnings results on Tuesday, August, 4th. The company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.06. The firm earned $12.53 billion during the quarter, compared to analysts' expectations of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive trailing twelve-month return on equity of 16.77%. Does Bayer Aktiengesellschaft have any subsidiaries? Bayer Aktiengesellschaft subsidiaries include these companies: Asklepios BioPharmaceutical, Care/of, KaNDy Therapeutics, BlueRock Therapeutics, Monsanto Company, Zoner.ag, Dihon Pharmaceutical, and others. How do I buy shares of Bayer Aktiengesellschaft? Shares of BAYRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/04/2026Today9/11/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:BAYRY CIK1144145 Webwww.bayer.com Phone49214301Fax49-21-4306-6328Employees88,078Year Founded1863Profitability EPS (Trailing Twelve Months)($0.51) Trailing P/E RatioN/A Forward P/E Ratio10.99 P/E Growth2.15Net Income-$4.10 billion Net Margins-3.80% Pretax Margin-2.10% Return on Equity16.77% Return on Assets4.53% Debt Debt-to-Equity Ratio1.05 Current Ratio1.04 Quick Ratio0.67 Sales & Book Value Annual Sales$51.55 billion Price / Sales1.07 Cash Flow$2.14 per share Price / Cash Flow6.56 Book Value$7.50 per share Price / Book1.88Miscellaneous Outstanding Shares3,930,000,000Free FloatN/AMarket Cap$55.30 billion OptionableNot Optionable Beta0.56 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:BAYRY) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bayer Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Bayer Aktiengesellschaft With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.